Nurix Therapeutics (NASDAQ:NRIX) Releases Quarterly Earnings Results, Misses Estimates By $0.18 EPS

Nurix Therapeutics (NASDAQ:NRIX) announced its quarterly earnings data on Wednesday. The company reported ($0.59) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by ($0.18), Fidelity Earnings reports.

Nurix Therapeutics stock traded down $0.91 during midday trading on Thursday, reaching $23.74. 32 shares of the company’s stock were exchanged, compared to its average volume of 230,128. Nurix Therapeutics has a 52 week low of $15.21 and a 52 week high of $37.46. The firm has a 50-day moving average price of $27.83.

NRIX has been the subject of several analyst reports. Piper Sandler initiated coverage on Nurix Therapeutics in a report on Tuesday, August 18th. They issued an “overweight” rating and a $40.00 price objective for the company. JPMorgan Chase & Co. initiated coverage on Nurix Therapeutics in a report on Tuesday, August 18th. They issued an “overweight” rating and a $35.00 price objective for the company. Needham & Company LLC initiated coverage on Nurix Therapeutics in a report on Tuesday, August 18th. They issued a “buy” rating and a $35.00 price objective for the company. Finally, Stifel Nicolaus initiated coverage on Nurix Therapeutics in a report on Tuesday, August 18th. They issued a “buy” rating and a $34.00 price objective for the company.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's lead product candidates in preclinical stage include NX-2127, an orally available Bruton's tyrosine kinase degrader for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B inhibitor for immuno-oncology indications.

See Also: Why does the United States have a lingering trade deficit?

Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.